Liia D. Vainchtein

461 total citations
13 papers, 372 citations indexed

About

Liia D. Vainchtein is a scholar working on Oncology, Pharmacology and Food Science. According to data from OpenAlex, Liia D. Vainchtein has authored 13 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pharmacology and 3 papers in Food Science. Recurrent topics in Liia D. Vainchtein's work include Colorectal Cancer Treatments and Studies (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Pesticide Residue Analysis and Safety (3 papers). Liia D. Vainchtein is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Pesticide Residue Analysis and Safety (3 papers). Liia D. Vainchtein collaborates with scholars based in Netherlands and Switzerland. Liia D. Vainchtein's co-authors include Jan H.M. Schellens, Hilde Rosing, Jos H. Beijnen, Bas Thijssen, Els Wagenaar, Olaf van Tellingen, Dirk R. de Waart, Karin Mohrmann, Jurjen S. Lagas and Ronald P.J. Oude Elferink and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, International Journal of Pharmaceutics and Rapid Communications in Mass Spectrometry.

In The Last Decade

Liia D. Vainchtein

13 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liia D. Vainchtein Netherlands 9 268 114 61 57 46 13 372
Stéphanie van Hoppe Netherlands 12 257 1.0× 148 1.3× 53 0.9× 45 0.8× 67 1.5× 15 449
J.H.M. Schellens Netherlands 10 378 1.4× 141 1.2× 118 1.9× 86 1.5× 50 1.1× 15 528
Bas Thijssen Netherlands 12 205 0.8× 138 1.2× 37 0.6× 62 1.1× 17 0.4× 21 461
Justine L. Lam United States 11 243 0.9× 182 1.6× 111 1.8× 165 2.9× 27 0.6× 16 454
David J. Sweeny United States 13 128 0.5× 153 1.3× 33 0.5× 88 1.5× 22 0.5× 30 451
Vishal S. Narang United States 8 182 0.7× 104 0.9× 69 1.1× 47 0.8× 21 0.5× 10 345
Wei Duan China 7 253 0.9× 174 1.5× 76 1.2× 71 1.2× 61 1.3× 20 471
Y. Anne Pak United States 8 212 0.8× 71 0.6× 91 1.5× 107 1.9× 19 0.4× 9 355
G. Bastian France 12 237 0.9× 154 1.4× 28 0.5× 33 0.6× 36 0.8× 39 403
Xiaoping Chen China 14 244 0.9× 203 1.8× 30 0.5× 29 0.5× 61 1.3× 32 520

Countries citing papers authored by Liia D. Vainchtein

Since Specialization
Citations

This map shows the geographic impact of Liia D. Vainchtein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liia D. Vainchtein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liia D. Vainchtein more than expected).

Fields of papers citing papers by Liia D. Vainchtein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liia D. Vainchtein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liia D. Vainchtein. The network helps show where Liia D. Vainchtein may publish in the future.

Co-authorship network of co-authors of Liia D. Vainchtein

This figure shows the co-authorship network connecting the top 25 collaborators of Liia D. Vainchtein. A scholar is included among the top collaborators of Liia D. Vainchtein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liia D. Vainchtein. Liia D. Vainchtein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Joerger, Markus, Alwin D. R. Huitema, Henk Boot, et al.. (2015). Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75(4). 763–772. 47 indexed citations
2.
Joerger, Markus, J.A. Burgers, Paul Baas, et al.. (2011). Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemotherapy and Pharmacology. 69(1). 25–33. 26 indexed citations
3.
4.
Oostendorp, Roos L., Petronella O. Witteveen, Brian Schwartz, et al.. (2009). Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Investigational New Drugs. 28(2). 163–170. 22 indexed citations
5.
Vainchtein, Liia D., Hilde Rosing, Jan H.M. Schellens, & Jos H. Beijnen. (2008). Ultrasensitive Bioanalytical Assays for Cytotoxic Drugs: Focus on Locally Administered Anti-Cancer Agents. 2(1). 10–39. 1 indexed citations
6.
7.
Vainchtein, Liia D., Hilde Rosing, Armin Maier, et al.. (2007). Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry. Journal of Chromatography B. 856(1-2). 261–266. 4 indexed citations
8.
Vainchtein, Liia D., Hilde Rosing, Bas Thijssen, Jan H.M. Schellens, & Jos H. Beijnen. (2007). Validated assay for the simultaneous determination of the anti‐cancer agent gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma by high‐performance liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 21(14). 2312–2322. 30 indexed citations
9.
Vlaming, Maria L.H., Karin Mohrmann, Els Wagenaar, et al.. (2006). Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice. Journal of Pharmacology and Experimental Therapeutics. 318(1). 319–327. 118 indexed citations
10.
Vainchtein, Liia D., Hilde Rosing, Dorla Mirejovsky, et al.. (2006). Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high‐performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. Journal of Mass Spectrometry. 41(10). 1268–1276. 9 indexed citations
11.
Vainchtein, Liia D., Hilde Rosing, Dorla Mirejovsky, et al.. (2006). Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer. Journal of Pharmaceutical and Biomedical Analysis. 43(1). 285–292. 10 indexed citations
12.
Vainchtein, Liia D., et al.. (2006). EO-9 bladder instillations: Formulation selection based on stability characteristics and in vitro simulation studies. International Journal of Pharmaceutics. 329(1-2). 135–141. 4 indexed citations
13.
Vainchtein, Liia D., Bas Thijssen, Ellen Stokvis, et al.. (2005). A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomedical Chromatography. 20(1). 139–148. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stéphanie van Hoppe Breakdown of academic impact, for papers by J.H.M. Schellens Breakdown of academic impact, for papers by Bas Thijssen Breakdown of academic impact, for papers by Justine L. Lam Breakdown of academic impact, for papers by David J. Sweeny Breakdown of academic impact, for papers by Vishal S. Narang Breakdown of academic impact, for papers by Wei Duan Breakdown of academic impact, for papers by Y. Anne Pak Breakdown of academic impact, for papers by G. Bastian Breakdown of academic impact, for papers by Xiaoping Chen
Rankless by CCL
2026